Edition:
United States

Genmab A/S (GEN.CO)

GEN.CO on Copenhagen Stock Exchange

1,136.50DKK
20 Jul 2018
Change (% chg)

kr.11.50 (+1.02%)
Prev Close
kr.1,125.00
Open
kr.1,124.50
Day's High
kr.1,145.00
Day's Low
kr.1,122.00
Volume
129,720
Avg. Vol
235,170
52-wk High
kr.1,474.00
52-wk Low
kr.880.80

Summary

Name Age Since Current Position

Mats Pettersson

72 2013 Independent Chairman of the Board

Jan van de Winkel

56 2010 President and Chief Executive Officer

Deirdre Connelly

57 2018 Independent Deputy Chairman of the Board

David Eatwell

57 2008 Executive Vice President, Chief Financial Officer

Judith Klimovsky

60 2017 Executive Vice President, Chief Development Officer

Anthony Pagano

40 2011 Senior Vice President, Global Finance

Birgitte Stephensen

57 2010 Senior Vice President, IPR & Legal

Rachel Curtis Gravesen

49 2011 Senior Vice President, Investor Relations and Communications

Tahamtan Ahmadi

45 Senior Vice President, Oncology and Translational Medicine

Michael Bauer

54 2010 Senior Vice President, Clinical Development

Martine van Vugt

47 Senior Vice President, Strategic Initiatives

Daniel Bruno

38 2016 Director, Employee Representative

Anders Gersel Pedersen

66 2018 Director

Rick Hibbert

38 2016 Director, Employee Representative

Peter Storm Kristensen

43 2016 Director, Employee Representative

Pernille Erenbjerg

50 2015 Independent Director

Rolf Hoffman

58 2017 Independent Director

Paolo Paoletti

67 2015 Independent Director

Biographies

Name Description

Mats Pettersson

Mr. Mats Pettersson has been Independent Chairman of the Board of Directors of Genmab A/S since April 17, 2013. He has experience from international research-based biotech and pharmaceutical companies. He has been Founder and Chief Executive Officer of SOBI AB. He is responsible for several transforming Business Development deals and member of various executive management committees at Pharmacia. He is Member of the Board of Magle Chemoswed AB. Previously, he was Chairman of the Board of H. Lundbeck A/S and NsGene AS, and Member of the Boards of Ablynx NV, Biacore AB and Active Biotech AB. He holds Bachelor of Science degree.

Jan van de Winkel

Prof. Jan G. J. van de Winkel, Ph.D. has been President and Chief Executive Officer of Genmab A/S since 2010. He is Co-founder of the Company and has previously served as its President, Research & Development and Chief Scientific Officer. Earlier in his career, he worked as Vice President and Scientific Director of Medarex Europe. Prof. van de Winkel has held professorship in Immunotherapy at Utrecht University. He chairs the Board of Hookipa Biotech and serves as Member on the Boards of Directors of Leo Pharma and Celdara Medical, as well as Member of the Scientific Advisory Board of Capricorn Health-tech Fund and Thuja Capital Healthcare Fund. Prof. van de Winkel holds Master of Science and Doctorate of Philosophy degrees from the University of Nijmegen.

Deirdre Connelly

Ms. Deirdre P. Connelly has served as Independent Deputy Chairman of the Board of Genmab A/S since April 10, 2018. She has been Independent Member of the Board of Directors of Genmab A/S since March 28, 2017. She is Member of the Audit Committee and the Corporate Governance Committee of the Company. She has more than 30 years of experience as a corporate leader and extensive experience in corporate governance as a board member. She directed the launch of more than 20 new pharmaceutical drugs. She is former President, North America Pharmaceuticals for GlaxoSmithKline. She serves as Member of the Board of Directors of Macy's Inc. and Lincoln National Corporation.

David Eatwell

Mr. David A. Eatwell has served as Executive Vice President, Chief Financial Officer of Genmab A/S since 2008. Prior to joining the Company, he was Chief Financial Officer (CFO) of Catalent Pharma Solutions, Inc., and before that, a divisional CFO of Cardinal Health, Inc. Mr. Eatwell is Member of the Association of Chartered Certified Accountants. He has broad international experience in finance, strategy and business management and in-depth knowledge of the pharmaceutical and biotechnology industries.

Judith Klimovsky

Dr. Judith Klimovsky, M.D. has been appointed Executive Vice President and Chief Development Officer at Genmab A/S, effective as of February 13, 2017. Dr. Klimovsky came from a role as Senior Vice President and Global Head, Oncology Clinical Development at Novartis. She is a recognized drug development leader in the pharmaceutical industry and has previously served in senior roles at Merck and Bristol-Meyers Squibb. Dr. Klimovsky has also held positions in clinical practice in Buenos Aires, Argentina.

Anthony Pagano

Mr. Anthony Pagano has served as Senior Vice President, Global Finance at Genmab A/S since 2011. He joined the Company in 2007. Prior to joining, he was Corporate Controller and Senior Director of Business Planning at NovaDel Pharma. He started his career at KPMG LLP, reaching the position of Manager, where he provided audit and M&A consulting services. Mr. Pagano is a Certified Public Accountant and received Bachelor of Science degree in Accounting from The College of New Jersey. He has knowledge and experience in the life sciences industry particularly as relates to corporate finance, corporate development, strategic planning, general management, treasury, accounting and corporate governance.

Birgitte Stephensen

Ms. Birgitte Stephensen has been Senior Vice President, IPR & Legal at Genmab A/S since 2010. She joined the Company in 2002. She holds Master of Science degree from the Danish University of Pharmaceutical Sciences (currently a faculty within Koebenhavns Universitet). She has also passed the European Qualifying Examination as European Patent Attorney in 1994. She has experience in intellectual property and legal expertise in the biotechnology field.

Rachel Curtis Gravesen

Ms. Rachel Curtis Gravesen has been Senior Vice President, Investor Relations and Communications at Genmab A/S since May 1, 2011. In the past, she worked in investor relations and corporate communications within the healthcare sector and prior to that as a journalist at the financial news channel CNBC and the BBC in London. She had previously served for the Company having established the investor and public relations functions after the Company's IPO. Most recently, she was responsible for corporate communications at Novo Nordisk, where she specialized in critical issues management and media relations as well as working with internal communications. She holds Master of Arts degree awarded by St John’s College, University of Cambridge and a postgraduate in Journalism from City University in London.

Tahamtan Ahmadi

Mr. Tahamtan Ahmadi, M.D., Ph.D. serves as Senior Vice President, Oncology and Translational Medicine at GENMAB A/S. He has significant expertise in global regulatory and clinical drug development across entire spectrum from pre IND to life cycle management; drug discovery and translational research.

Michael Bauer

Dr. Michael K. Bauer, Ph.D. has served as Senior Vice President, Clinical Development at Genmab A/S since 2010. He joined the Company in 2006. Before that, he held various positions in academia, the pharmaceutical industry and the venture finance sector in Germany, New Zealand, the United States and Denmark. He holds Master of Science degree from the Universitaet Hohenheim, Stuttgart, and a Doctorate of Philosophy degree from Georg-August-Universitaet Goettingen (University of Gottingen, Germany). He has wide, international scientific and pharmaceutical industry background, as well as significant experience in clinical drug development; cross-functional and cross-cultural strategic leadership.

Martine van Vugt

Ms. Martine J. van Vugt, Ph.D. serves as Senior Vice President, Strategic Initiatives at Genmab A/S. She has knowledge and experience in portfolio, project and alliance management, as well as business development operations related to corporate transactions and licensing.

Daniel Bruno

Mr. Daniel J. Bruno has served as Employee Representative on the Board of Directors of Genmab A/S since March 17, 2016. He previously was Director, Employee Representative from 2010 until April 17, 2013. He is Vice President, Corporate Controller at the Company. He joined the Company in 2008 and served as Senior Director, Accounting and Finance. Prior to this, he spent six years at PricewaterhouseCoopers in the Assurance and Business Advisory practice. Mr. Bruno is a Certified Public Accountant. He holds Bachelor of Science and Master of Science degrees from Fairleigh Dickinson University.

Anders Gersel Pedersen

Dr. Anders Gersel Pedersen, M.D., Ph.D. has been Director of Genmab A/S since April 10, 2018. He has previously been Deputy Chairman of the Board of Directors of Genmab A/S since 2015. Previously, he was Independent Deputy Chairman of the Board of Directors of Genmab A/S from April 17, 2013 until 2015. Before that, he has been Independent Chairman of the Board of Directors of the Company since 2012. He joined the Company’s Board in 2003, and was appointed Independent Deputy Chairman in 2005. He is Chairman of the Compensation Committee and Member of the Scientific Committee. Dr. Gersel Pedersen is Executive Vice President, Research & Development at H. Lundbeck A/S. During the course of his career, he has held a number of Research Fellow positions at Copenhagen hospitals. In addition, he serves on the board of ALK-Abello A/S and is Deputy Chairman of the Board of Bavarian Nordic A/S. Dr. Gersel Pedersen has received his Medical degree and a Doctoral degree in Neuro-oncology from Koebenhavns Universitet and a Bachelor of Science degree in Business Administration from Copenhagen Business School.

Rick Hibbert

Dr. Rick Hibbert, Ph.D. has been Director, Employee Representative at Genmab A/S since March 17, 2016. He has 15 years’ experience in the life-sciences sector, with expertise in down-stream processing, biochemistry and structural biology. He is Assistant Director, Protein Production and Chemistry at Genmab. He holds MBA degree.

Peter Storm Kristensen

Mr. Peter Storm Kristensen has been Director, Employee Representative at Genmab A/S since March 17, 2016. He has broad legal experience within the pharmaceutical industry with specialty in corporate law, securities law, human resources law as well as drafting and negotiating contracts in general. He is Associate Director, Legal at Genmab.

Pernille Erenbjerg

Ms. Pernille Erenbjerg has been Independent Member of the Board of Directors of Genmab A/S since March 26, 2015. She has senior executive management and broad business experience from the telecoms industry and Certified Public Accountant background. She holds Master of Science degree in Business Economics from Copenhagen Business School (1992). She is Group CEO and President of TDC A/S. She is also Member of the Board and Member of the Audit Committee of Nordea AB and Vice Chairman and Chairman of Audit Committee of DFDS A/S.

Rolf Hoffman

Mr. Rolf K. Hoffmann has served as Independent Member of the Board of Directors of Genmab A/S since March 28, 2017. He is Member of the Compensation Committee and the Scientific Committee of the Company. He has international management experience with expertise in creating and optimizing commercial opportunities in global markets, as well as additional expertise in P&L management, governance and Corporate Integrity Agreement Management, compliance and organizational efficiency. He has over 20 years of experience in the international pharmaceutical and biotechnology industries at Eli Lilly and Amgen. He serves as Adjunct Professor Strategy and Entrepreneurship University of North Carolina Business School. He is also Member of the Board of Directors of EUSA Pharma, Inc and Trigemina, Inc., as well as Chairman of Biotest AG. Previously, he held Board Positions at Swiss-American Chamber of Commerce, Council of Americas, International School of Zug and Luzern, University of North Carolina at Chapel Hill, International Advisory Board.

Paolo Paoletti

Dr. Paolo Paoletti, M.D. has been Independent Member of the Board of Directors of Genmab A/S since March 26, 2015. He is Chairman of the Scientific Committee. He has extensive experience in research, development and commercialization in the pharmaceutical industry and he successfully conducted submissions and approvals of new cancer drugs and new indications in the USA and in Europe. He was responsible for seven new medicines for cancer patients during his 10 years at GlaxoSmithKline and one new cancer medicine during his time at Eli Lilly. His last position in GSK was President of Oncology Business Unit. He is CEO of GammaDelta Therapeutics Limited and Chairman of the Board of PsiOxus Therapeutics Limited, as well as Member of the Board of FORMA Therapeutics.